Rockefeller Capital Management

Rockefeller Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Rockefeller Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$462K	Sell	19,597 -31,988	-62%	-$816K	﹤0.01%	2018
2025 Q4	$1.5M	Buy	51,585 +12,646	+32%	+$324K	﹤0.01%	1376
2025 Q3	$734K	Buy	38,939 +17,845	+85%	+$281K	﹤0.01%	1581
2025 Q2	$296K	Buy	21,094 +2,637	+14%	+$37K	﹤0.01%	1653
2025 Q1	$289K	Buy	+18,457	New	+$260K	﹤0.01%	1599
2021 Q2	–	Sell	-1,000	Closed	-$28K	–	3433
2021 Q1	$28K	Hold	1,000	–	–	﹤0.01%	2124
2020 Q4	$28K	Buy	+1,000	New	+$24.5K	﹤0.01%	1871

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return